Compare Brown-Forman Corporation Class B (BF.B) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brown-Forman Corporation Class B vs 10X Genomics Inc — how do they compare? Brown-Forman Corporation Class B trades at $28.01, while 10X Genomics Inc trades at $59.38 (market cap $7.64B). The key difference: 10X Genomics Inc is trading nearer its 52-week high, Brown-Forman Corporation Class B nearer its low. Which is the better fit depends on your goals.
| BF.B | TXG | |
|---|---|---|
Sector | Consumer Staples | Health |
52-Week High | $31.26 | $58.57 |
52-Week Low | $22.80 | $11.34 |
Market Cap | — | $7.64B |
Enterprise Value | — | $7.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BF.B trades at $28.52, up 0.88% today, with a bullish technical signal from moving averages and strong trend strength (ADX). Earnings have beaten estimates in three of the last four quarters, with Q2 2024 EPS of $0.48 exceeding the $0.46 forecast. The stock faces mixed analyst sentiment but shows consistent fundamental performance.
The outlook is cautiously optimistic given recent earnings strength, though limited analyst coverage and mixed ratings suggest uncertainty. Key risks include execution challenges and market volatility. Upside potential hinges on sustained earnings growth and broader market conditions.
TXG is trading at $52.03, up 14.1% in the past 24 hours, reflecting strong momentum. The stock exhibits a bullish technical signal with moving averages supporting upward trends, while RSI levels suggest mild overbought conditions. Fundamentally, the company reported Q2 2026 revenue of $151 million, beating estimates, and has shown consistent earnings beats in recent quarters. Recent news highlights collaborations with Cleveland Clinic and the acquisition of Proteintech Genomics, expanding its multiomics capabilities and reinforcing growth prospects.
The outlook for TXG is cautiously optimistic, driven by earnings outperformance and strategic expansions, but risks include persistent net losses and high valuation multiples. Analyst consensus is mixed with a $46 price target, indicating potential downside from current levels. Investors should weigh revenue growth against profitability challenges and monitor execution on new initiatives for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Brown-Forman Corporation Class B
Brown-Forman is the largest U.S.-domiciled producer of distilled spirits. The firm reports only a single operating segment, and whiskey represents its primary business driver, generating roughly three-quarters of sales, undergirded by the Jack Daniel's brand as well as bourbons such as Woodford Reserve and Old Forrester. Notable nonwhiskey offerings include tequilas such as el Jimador and Herradura. The firm operates globally, with products sold in more than 170 countries, and adapts its route-to-consumer model depending on regulation as well as the prevailing competitive dynamics in a given market. For example, it sells through distributors in the U.S. but operates its own logistics apparatus in many other countries. The company remains under the control of the Brown family.
Read more on BF.B →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
